Literature DB >> 18311797

Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus.

Trina Thompson1, Kim Sutton-Tyrrell, Rachel P Wildman, Amy Kao, Shirley G Fitzgerald, Betsy Shook, Russell P Tracy, Lewis H Kuller, Sarah Brockwell, Susan Manzi.   

Abstract

OBJECTIVE: Women with systemic lupus erythematosus (SLE) are at high risk of cardiovascular disease (CVD). The goals of this study were to determine the extent of atherosclerotic progression among women with SLE compared with a group of healthy controls and to determine whether factors attributed to SLE or its treatment were associated with atherosclerotic progression independent of traditional CVD risk factors.
METHODS: A longitudinal study of women with SLE from the Pittsburgh Lupus Registry was conducted. Women 18 years of age and older (n = 217) underwent carotid ultrasound at baseline and at followup, an average of 4.19 years later. Clinical, serologic, and SLE-related factors, and disease treatment were evaluated. Outcomes were changes in carotid intima-media thickness (IMT) and plaque. Progression of CVD in a sample of women without lupus was used for comparison.
RESULTS: The patients' mean +/- SD age at baseline was 45.1 +/- 10.3 years, and the mean +/- SD IMT progression rate was 0.011 +/- 0.03 mm per year. After controlling for traditional CVD risk factors, higher serum creatinine levels were associated with IMT progression (P = 0.0006). Plaque prevalence was 31% at baseline and 40% at followup; plaque progression occurred in 27% of the patients. Higher serum C3 levels and immunosuppressant use at baseline were related to plaque progression (P = 0.04 and P = 0.02, respectively) independent of traditional CVD risk factors. The plaque progression rate was higher than, and the IMT progression rate was similar to, those in the control group.
CONCLUSION: SLE patients have accelerated plaque progression compared with controls. SLE-related risk factors are associated with the progression of IMT and plaque after controlling for traditional CVD risk factors. Carotid B-mode ultrasound may serve as a surrogate end point in SLE intervention trials and clinically to track SLE management.

Entities:  

Mesh:

Year:  2008        PMID: 18311797     DOI: 10.1002/art.23196

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  58 in total

Review 1.  Chronic Inflammatory Diseases and Endothelial Dysfunction.

Authors:  Xavier Castellon; Vera Bogdanova
Journal:  Aging Dis       Date:  2016-01-02       Impact factor: 6.745

2.  Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus.

Authors:  April Jorge; Apinya Lertratanakul; Jungwha Lee; William Pearce; David McPherson; Trina Thompson; Emma Barinas-Mitchell; Rosalind Ramsey-Goldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-11-21       Impact factor: 4.794

3.  Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus.

Authors:  A N Kiani; P Aukrust; T Ueland; I Hollan; E Barr; L S Magder; M Petri
Journal:  Lupus       Date:  2016-12-06       Impact factor: 2.911

4.  Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Sara Kaprove Penn; Amy H Kao; Laura L Schott; Jennifer R Elliott; Frederico G S Toledo; Lewis Kuller; Susan Manzi; Mary Chester M Wasko
Journal:  J Rheumatol       Date:  2010-05-01       Impact factor: 4.666

Review 5.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

6.  Trajectories of estradiol and follicle-stimulating hormone over the menopause transition and early markers of atherosclerosis after menopause.

Authors:  Samar R El Khoudary; Nanette Santoro; Hsiang-Yu Chen; Ping G Tepper; Maria M Brooks; Rebecca C Thurston; Imke Janssen; Sioban D Harlow; Emma Barinas-Mitchell; Faith Selzer; Carol A Derby; Elizabeth A Jackson; Daniel McConnell; Karen A Matthews
Journal:  Eur J Prev Cardiol       Date:  2015-09-18       Impact factor: 7.804

Review 7.  Global trends, potential mechanisms and early detection of organ damage in SLE.

Authors:  Anselm Mak; David A Isenberg; Chak-Sing Lau
Journal:  Nat Rev Rheumatol       Date:  2012-12-11       Impact factor: 20.543

8.  Subclinical atherosclerosis in systemic lupus erythematosus patients and its relationship to disease activity and damage indices.

Authors:  S Fadda; H Nassar; S M Gamal; H Al-azizi
Journal:  Z Rheumatol       Date:  2015-08       Impact factor: 1.372

Review 9.  Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Annamaria Margarita; Jose Delgado Alves
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

10.  Low socioeconomic status over 12 years and subclinical cardiovascular disease: the study of women's health across the nation.

Authors:  Rebecca C Thurston; Samar R El Khoudary; Carol A Derby; Emma Barinas-Mitchell; Tené T Lewis; Candace K McClure; Karen A Matthews
Journal:  Stroke       Date:  2014-02-27       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.